Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 164

The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.

Discovery and clinical introduction of first-in-class imipridone ONC201

Open access
Allen, Joshua E., Kline, C. Leah B., Prabhu, Varun V., Wagner, Jessica, Ishizawa, Jo, Madhukar, Neel, Lev, Avital, Baumeister, Marie, Zhou, Lanlan, Lulla, Amriti, Stogniew, Martin, Schalop, Lee, Benes, Cyril, Kaufman, Howard L., Pottorf, Richard S., Nallaganchu, B. Rao, Olson, Gary L., Al-Mulla, Fahd, Duvic, Madeleine, Wu, Gen Sheng, Dicker, David T., Talekar, Mala K., Lim, Bora, Elemento, Olivier, Oster, Wolfgang, Bertino, Joseph, Flaherty, Keith, Wang, Michael L., Borthakur, Gautam, Andreeff, Michael, Stein, Mark, El-Deiry, Wafik S.·2016·Oncotarget

Abstract

// Joshua E. Allen 1 , C. Leah B. Kline 2 , Varun V. Prabhu 1 , Jessica Wagner 2 , Jo Ishizawa 3 , Neel Madhukar 4 , Avital Lev 2 , Marie Baumeister 2 , Lanlan Zhou 2 , Amriti Lulla 2 , Martin Stogniew 1 , Lee Schalop 1 , Cyril Benes 5,6 , Howard L. Kaufman 7 , Richard S. Pottorf 8 , B. Rao Nallaganchu 8 , Gary L. Olson 8 , Fahd Al-Mulla 9 , Madeleine Duvic 3 , Gen Sheng Wu 10 , David T. Dicker 2 , Mala K. Talekar 11 , Bora Lim 3 , Olivier Elemento 4 , Wolfgang Oster 1 , Joseph Bertino 7 , Keith Flaherty 5,6 , Michael L. Wang 3 , Gautam Borthakur 3 , Michael Andreeff 3 , Mark Stein 7 and Wafik S. El-Deiry 2 1 Oncoceutics, Inc., Philadelphia, PA, USA 2 Fox Chase Cancer Center, Philadelphia, PA, USA 3 University of Texas MD Anderson Cancer Center, Houston, TX, USA 4 Weill Cornell Medicine, New York, NY, USA 5 Massachusetts General Hospital, Boston, MA, USA 6 Harvard Medical School, Boston, MA, USA 7 Rutgers Cancer Institute of New Jersey, New Brunswick, NJ, USA 8 Provid Pharmaceuticals, Monmouth Junction, NJ, USA 9 Kuwait University Medical School, Kuwait 10 Karmanos Cancer Institute, Detroit, MI, USA 11 The Children’s Hospital of Philadelphia, Philadelphia, PA, USA Correspondence to: Wafik S. El-Deiry, email: // Keywords : ONC201, TIC10, integrated stress response, ATF4, DRD2 Received : August 23, 2016 Accepted : August 30, 2016 Published : September 01, 2016 Abstract ONC201 is the founding member of a novel class of anti-cancer compounds called imipridones that is currently in Phase II clinical trials in multiple advanced cancers. Since the discovery of ONC201 as a p53-independent inducer of TRAIL gene transcription, preclinical studies have determined that ONC201 has anti-proliferative and pro-apoptotic effects against a broad range of tumor cells but not normal cells. The mechanism of action of ONC201 involves engagement of PERK-independent activation of the integrated stress response, leading to tumor upregulation of DR5 and dual Akt/ERK inactivation, and consequent Foxo3a activation leading to upregulation of the death ligand TRAIL. ONC201 is orally active with infrequent dosing in animals models, causes sustained pharmacodynamic effects, and is not genotoxic. The first-in-human clinical trial of ONC201 in advanced aggressive refractory solid tumors confirmed that ONC201 is exceptionally well-tolerated and established the recommended phase II dose of 625 mg administered orally every three weeks defined by drug exposure comparable to efficacious levels in preclinical models. Clinical trials are evaluating the single agent efficacy of ONC201 in multiple solid tumors and hematological malignancies and exploring alternative dosing regimens. In addition, chemical analogs that have shown promise in other oncology indications are in pre-clinical development. In summary, the imipridone family that comprises ONC201 and its chemical analogs represent a new class of anti-cancer therapy with a unique mechanism of action being translated in ongoing clinical trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.18632/oncotarget.11814

Cites

3 of 3 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 3 references

Cited by

See all 164

Metadata

Authors
Allen, J. E., Kline, C. L. B., Prabhu, V. V., Wagner, J., Ishizawa, J., Madhukar, N., Lev, A., Baumeister, M., Zhou, L., Lulla, A., Stogniew, M., Schalop, L., Benes, C., Kaufman, H. L., Pottorf, R. S., Nallaganchu, B. R., Olson, G. L., Al-Mulla, F., Duvic, M., Wu, G. S., Dicker, D. T., Talekar, M. K., Lim, B., Elemento, O., Oster, W., Bertino, J., Flaherty, K., Wang, M. L., Borthakur, G., Andreeff, M., Stein, M., & El-Deiry, W. S.
Venue
Oncotarget
Published
2016-09-01
Volume
7
Issue
45
Pages
74380-74392
ISSN
1949-2553 (ISSN-L)
OpenAlex
W2514974106
Cited by
164
References
3
FWCI
6.32
Type
journal article
Language
en
Open access
diamond

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Discovery and clinical introduction of first-in-class imipridone ONC201. https://app.cochat.ai/papers/10.18632/oncotarget.11814
The paper
Allen, J. E., Kline, C. L. B., Prabhu, V. V., Wagner, J., Ishizawa, J., Madhukar, N., Lev, A., Baumeister, M., Zhou, L., Lulla, A., Stogniew, M., Schalop, L., Benes, C., Kaufman, H. L., Pottorf, R. S., Nallaganchu, B. R., Olson, G. L., Al-Mulla, F., Duvic, M., . . . El-Deiry, W. S. (2016). Discovery and clinical introduction of first-in-class imipridone ONC201. Oncotarget. https://doi.org/10.18632/oncotarget.11814

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.